Haemonetics (HAE) Expected to Release Quarterly Earnings on Thursday

Key Points

• Haemonetics is expected to report Q2 fiscal 2027 results before market open on November 5, 2026. Analysts forecast earnings of $1.29 per share on revenue of $345.15 million.
• In the previous quarter, Haemonetics exceeded estimates with EPS of $1.14 versus $1.08 expected and revenue of $339.38 million, up 5.5% year over year.
• Analysts maintain a Moderate Buy consensus, with recent price-target increases ranging from $119 to $140, although the stock was down 1.5% and trading near its 12-month high.

Haemonetics (NYSE:HAE - Get Free Report) will likely be announcing its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect Haemonetics to announce earnings of $1.29 per share and revenue of $345.15 million for the quarter. Individuals can find conference call details on the company's upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. The company had revenue of $339.38 million for the quarter, compared to analysts' expectations of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business's revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.10 EPS. On average, analysts expect Haemonetics to post $5.29 EPS for the current fiscal year and $5.73 EPS for the next fiscal year.

Haemonetics Stock Down 1.5%

Shares of Haemonetics stock opened at $118.19 on Thursday. Haemonetics has a 12-month low of $48.98 and a 12-month high of $123.77. The firm has a market capitalization of $5.38 billion, a PE ratio of 57.94, a price-to-earnings-growth ratio of 2.37 and a beta of 0.61. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The stock's fifty day moving average is $109.56 and its 200-day moving average is $78.48.

Analyst Ratings Changes

HAE has been the subject of several recent analyst reports. Robert W. Baird raised their target price on shares of Haemonetics from $96.00 to $119.00 and gave the stock an "outperform" rating in a report on Friday, August 21st. Wall Street Zen upgraded shares of Haemonetics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Raymond James Financial boosted their target price on shares of Haemonetics from $105.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, September 3rd. BTIG Research increased their target price on Haemonetics from $110.00 to $130.00 and gave the company a "buy" rating in a report on Thursday, October 8th. Finally, Barrington Research increased their target price on Haemonetics from $118.00 to $140.00 and gave the company an "outperform" rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.00.

About Haemonetics

Haemonetics Corporation NYSE: HAE is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company's offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.